---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-011557"
form_type: "8-K"
ticker: "MGRX"
cik: "0001938046"
company_name: "MANGOCEUTICALS, INC."
filed_at: "2025-08-04T23:59:59+00:00"
generated_at: "2026-05-17T21:36:39.989691+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Mangoceuticals terminates Diabetinol licensing deal; cancels 1M shares issued to Navy Wharf

## Summary
- Mutually rescinded March 2025 Master Distribution Agreement for Diabetinol, effective July 30, 2025.
- No material early termination penalties incurred by Mangoceuticals.
- Navy Wharf agreed to cancel all 1,000,000 previously issued restricted shares as consideration.
- Unrelated: warrant holder exercised 198,000 warrants at $1.50, raising $297,000 for the company.

## SEC filing metadata
- accession: 0001493152-25-011557
- form_type: 8-K
- ticker: MGRX
- cik: 0001938046
- company_name: MANGOCEUTICALS, INC.
- filed_at: 2025-08-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 1.02, 2.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1938046/000149315225011557/0001493152-25-011557-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1938046/000149315225011557/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-011557
- JSON: https://secwatch.observer/filing/0001493152-25-011557.json
- Plain text: https://secwatch.observer/filing/0001493152-25-011557.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.